patient subgroup...
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
interferon - versus standard of care - for COVID 19 hospitalized
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.59 [0.13, 2.76]< 1 27% 3 studies (3/-) 74.6 % high not evaluable low crucial - deaths 0.43 [0.25, 0.76]< 1 0% 8 studies (8/-) 99.8 % some concern serious moderate crucial - deaths (time to event analysis only) 0.38 [0.16, 0.87]< 1 0% 1 study (1/-) 98.8 % NA not evaluable crucial - clinical deterioration 2.29 [0.20, 26.58]< 1 0% 1 study (1/-) 25.6 % NA not evaluable important - clinical improvement 1.29 [0.69, 2.42]> 1 48% 3 studies (3/-) 78.8 % some concern not evaluable moderate important - clinical improvement (14-day) 2.03 [0.17, 24.32]> 1 75% 2 studies (2/-) 71.0 % some concern not evaluable moderate important - clinical improvement (7-day) 1.91 [1.03, 3.53]> 1 0% 1 study (1/-) 98.0 % NA not evaluable important - clinical improvement (time to event analysis only) 1.73 [1.05, 2.86]> 1 45% 4 studies (4/-) 98.4 % some concern not evaluable moderate important - hospital discharge 2.24 [0.99, 5.10]> 1 0% 2 studies (2/-) 97.3 % high not evaluable low important - mechanical ventilation 0.74 [0.41, 1.34]< 1 0% 4 studies (4/-) 84.1 % some concern not evaluable moderate important - viral clearance 2.89 [1.81, 4.62]> 1 0% 3 studies (3/-) 100.0 % some concern not evaluable moderate important - viral clearance (time to event analysis only) 3.26 [1.53, 6.95]> 1 0% 1 study (1/-) 99.9 % NA not evaluable important - viral clearance by day 14 0.55 [0.00, 227.28]> 1 96% 3 studies (3/-) 42.6 % some concern not evaluable moderate important - viral clearance by day 7 2.78 [1.65, 4.68]> 1 0% 3 studies (3/-) 100.0 % some concern not evaluable moderate important - ICU admission 0.49 [0.24, 1.00]< 1 0% 3 studies (3/-) 97.4 % some concern not evaluable moderate non important - off oxygenation 8.57 [1.43, 51.36]> 1 0% 1 study (1/-) 99.0 % NA not evaluable non important - 00 serious adverse events 0.95 [0.02, 50.33]< 1 0% 1 study (1/-) 51.0 % NA not evaluable important - superinfection 0.77 [0.06, 9.89]< 1 76% 2 studies (2/-) 57.8 % high not evaluable low important - adverse events 1.47 [0.65, 3.34]< 1 0% 2 studies (2/-) 17.9 % high not evaluable low non important -
LoD: level of statistical demonstration:
